SCHEMBL4513738

SCHEMBL4513738

CCOc1cccc(Cl)c1CC1CCN(C2CCCCC2)C1=O

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.52
LMNA P02545 6/20 0.38
TP53 P04637 4/20 0.38
POLB P06746 3/20 0.38
MAPT P10636 1/20 0.38
GAA P10253 1/20 0.36
KMT2A Q03164 1/20 0.36
ALDH1A1 P00352 4/20 0.36
KDM4E B2RXH2 3/20 0.36
TDP1 Q9NUW8 2/20 0.36
HRH3 Q9Y5N1 1/20 0.36
TSHR P16473 2/20 0.35
HTR2A P28223 1/20 0.35
HTR2C P28335 1/20 0.35
HTR2B P41595 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4516365 0.89 HSD11B1 (0.54) HSD11B1LMNATP53MAPTGAA
SCHEMBL5541309 0.89 HSD11B1 (0.49) HSD11B1LMNATP53GAAKMT2A
SCHEMBL4523062 0.88 HSD11B1 (0.48) HSD11B1LMNAPOLBGAAKMT2A
SCHEMBL4501877 0.88 HSD11B1 (0.44) HSD11B1LMNAPOLBGAAKMT2A
SCHEMBL4516411 0.87 HSD11B1 (0.47) HSD11B1LMNA
SCHEMBL4508316 0.86 HSD11B1 (0.49) HSD11B1LMNAPOLBGAAKMT2A
SCHEMBL3553955 0.86 HSD11B1 (0.64) HSD11B1LMNAPOLBMAPTKMT2A
SCHEMBL4516874 0.82 HSD11B1 (0.60) HSD11B1LMNATP53POLBMAPT
SCHEMBL2988726 0.82 HSD11B1 (0.59) HSD11B1LMNAPOLBMAPTGAA
SCHEMBL2990265 0.82 HSD11B1 (0.59) HSD11B1LMNAPOLBMAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
EP-1864971-A1 PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES Takeda Pharmaceutical Company Limited (JP) 2007-12-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes HSD11B1, HSD17B1, HSD11B2 HSD11B1 1/4885LMNA 2846/4885TP53 3134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.